Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:
a. Afatinib
b. Alectinib
c. Atezolizumab monotherapy
d. Atezolizumab in combination
e. Bevacizumab
f. Brigatinib
g. Capmatenib
h. Ceritinib
i. Crizotinib
j. Dacomitinib
k. Dabrafenib with Trametinib
l. Docetaxel monotherapy
m. Durvalumab
n. Erlotinib
o. Gefitinib
p. Gemcitabine
q. Nintedanib with Docetaxel
r. Nivolumab
s. Osimertinib
t. Paclitaxel
u. Pembrolizumab monotherapy
v. Pembrolizumab in combination
w. Pemetrexed with Carboplatin/Cisplatin
x. Tepotinib
y. Vinorelbine with Cisplatin/Carboplatin
z. Any other SACT
aa. Palliative care only
